Mahamaya Lifesciences logo

Mahamaya Lifesciences financials and balance sheet

BSE: 544611Fertilizers & AgrochemicalsSmall Cap

Last close ₹167.00down ₹2.00 (1.18%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹169.00.

Range of traded prices from listing on 18 Nov 2025 to 23 Oct 2026
₹111.00Low, 19 Nov 2025₹205.05High, 19 Dec 2025
Market cap
₹391 Cr1,969th largest listed
P/E
23.7
P/B
3.2
Dividend yield
Nonesince listing in Nov 2025
ROE
13.6%
Debt to equity
0.74
Volume, BSE
9,600

1 year at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Mahamaya Lifesciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue329
  2. Materials and goods−275
  3. Employee costs−8.3
  4. Other expenses−13
  5. Operating profit33
  6. Depreciation−2.2
  7. Other income+1.2
  8. Finance costs−8.1
  9. Profit before tax24
  10. Tax−7.4
  11. Net profit17

What the company owns

  • Inventory₹141 Cr
  • Receivables₹71 Cr
  • Plant, investments and other assets₹59 Cr
  • Cash and bank₹39 Cr

What pays for it: net worth and liabilities

  • Net worth₹122 Cr
  • Borrowings₹91 Cr
  • Owed to suppliers₹64 Cr
  • Other liabilities₹33 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Mahamaya Lifesciences half-yearly results

₹ croreMar 2026Filed 25 May
Revenue from operations329
296
Materials and goods bought275
Employee costs8
Other expenses13
Operating profit before depreciation33
Operating margin10.1%
Materials, % of revenue83.6%
Employee costs, % of revenue2.5%
Other expenses, % of revenue3.8%
Depreciation and amortisation2
Operating profit after depreciation31
Other income1
Finance costs8
Profit before tax24
7
Net profit17
Net margin5.0%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2026Filed 25 May
122
Share capital23
Reserves99
91
183
5
Total assets310
44
266
Net debt51
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2026Filed 25 May
−29.5
−25.2
−59.0
Receivables−22.3
Inventories−40.8
Payables9.4
Other working capital−5.2
Tax paid−4.4
Capital spending8.8
Free cash flow−38.3
−15.6
80.5
Dividends paid0.0
Shares issued64.3
Net change in cash35.4
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2026Filed 25 May
Earnings per share₹8.33
Diluted earnings per share₹8.33
Book value per share₹52.10
Shareholder yield−18.2%
Market cap at the year end (₹ crore)352

Ratios

Consolidated, years to March.Mahamaya Lifesciences PE ratio and valuation

RatioMar 2026Filed 25 May
Return on equity13.6%
Return on capital employed14.5%
Cash conversion−178.7%
Interest cover3.8
Debt to equity0.74
Receivable days79
Inventory days187
Payable days86
Cash conversion cycle, days180
Working capital days145
Asset turnover1.06
Assets per rupee of net worth2.54
Sales per rupee of plant14.25
Capital spending to depreciation3.93

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
5.3%
Cash from operations against operating profit
−89.2%

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations−29.5
Cash from investing−15.6
Cash from financing80.5
Capital spending8.8
Dividends paid0.0
Shares issued for cash64.3
Borrowings raised35.2
Borrowings repaid2.6

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2026
Effective tax ratePublished threshold 17.16 per cent30.80
Tax charged less tax paid, % of profitOur threshold 10 percentage points12.53
A threshold marked as ours has no published figure; it is the line we read the check against.